Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.
暂无分享,去创建一个
Jared A. Christensen | E. Nakakura | Jeanne Shen | L. Nardo | M. Tempero | R. Wolff | B. Wolpin | A. Lowy | A. Ko | M. Malafa | E. Chiorean | P. Polanco | W. Hawkins | A. Narang | S. Darlow | B. Czito | C. Scaife | T. Donahue | M. Chiaro | M. Truty | J. Kunstman | D. Cardin | E. Dotan | V. Chung | J. Hardacre | M. Dillhoff | S. Reddy | M. Reyngold | C. Moravek | K. Klute | A. Masood | C. Fountzilas | N. Loconte | C. Vollmer | Jorge V. Obando | Al B. Benson | E. Glazer | Beth McCullough Rn | Senem Lubin | A. Benson | MD Al B. Benson III | MD E. Gabriela Chiorean | MD PhD Marco Del Chiaro | MD Margaret A. Tempero | MD Mokenge P. Malafa | MD Dana B. Cardin | MD Jared A. Christensen | MD Vincent Chung | MD Brian Czito | MD MS Mary Dillhoff | MD Timothy R. Donahue | MD Efrat Dotan | MD Christos Fountzilas | MD PhD Evan S. Glazer | MD Jeffrey Hardacre | MD William G. Hawkins | MD Kelsey Klute | MD Andrew H. Ko | M. M. John W. Kunstman | MD Noelle LoConte | MD Andrew M. Lowy | MD Ashiq Masood | MD Eric K. Nakakura | MD Amol K. Narang | MD PhD Lorenzo Nardo | MD Jorge Obando | MD Patricio M. Polanco | MD Sushanth Reddy | MD PhD Marsha Reyngold | MD Courtney Scaife | MD Jeanne Shen | MD MS Mark J. Truty | MD Charles Vollmer Jr | MD Robert A. Wolff | M. M. Brian M. Wolpin | Cmsrn Beth McCullough RN | PhD Senem Lubin | PhD Susan D. Darlow
[1] T. Seufferlein,et al. Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Quality of life results of the randomized phase II AIO-NEONAX trial. , 2023, Journal of Clinical Oncology.
[2] G. Abou-Alfa,et al. 55P Final results from the NIFTY trial, a phase IIb, randomized, open-label study of liposomal Irinotecan (nal-IRI) plus fluorouracil (5-FU)/leucovorin (LV) in patients (pts) with previously treated metastatic biliary tract cancer (BTC) , 2022, Annals of Oncology.
[3] A. Saborowski,et al. 53MO Nal-IRI and 5-FU/LV compared to 5-FU/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC – AIO-HEP-0116) , 2022, Annals of Oncology.
[4] A. Drilon,et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. , 2022, The Lancet. Oncology.
[5] A. Singhi,et al. Neoadjuvant Therapy Versus Upfront Resection for Nonpancreatic Periampullary Adenocarcinoma , 2022, Annals of Surgical Oncology.
[6] J. Meyerhardt,et al. Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial. , 2022, JAMA oncology.
[7] J. W. Kim,et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. , 2022, NEJM evidence.
[8] Song-Cheol Kim,et al. Controversial benefit of 5-fluorouracil/leucovorin-based adjuvant chemotherapy for ampullary cancer: a propensity score-matched analysis , 2022, Langenbeck's Archives of Surgery.
[9] A. Sauvanet,et al. The long-term outcomes of laparoscopic versus open pancreatoduodenectomy for ampullary carcinoma showed similar survival: a case-matched comparative study , 2021, Surgical Endoscopy.
[10] K. Ichimura,et al. The Impact of KRAS Mutation in Patients With Sporadic Nonampullary Duodenal Epithelial Tumors , 2021, Clinical and translational gastroenterology.
[11] E. Van Cutsem,et al. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] T. Aoki,et al. Efficacy and Feasibility of Adjuvant Gemcitabine Plus Cisplatin Chemotherapy After Major Hepatectomy for Biliary Tract Cancer , 2021, AntiCancer Research.
[13] J. Berlin,et al. Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513 , 2021, Clinical Cancer Research.
[14] R. Shen,et al. Genome-Derived Classification Signature for Ampullary Adenocarcinoma to Improve Clinical Cancer Care , 2021, Clinical Cancer Research.
[15] J. Hainsworth,et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. , 2021, The Lancet. Oncology.
[16] D. Berton,et al. Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability–high tumors: A combined analysis of two cohorts in the GARNET study. , 2021 .
[17] W. Ryder,et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial , 2021, The Lancet. Oncology.
[18] S. Bozzarelli,et al. Long-term outcomes after pancreatoduodenectomy for ampullary cancer: The influence of the histological subtypes and comparison with the other periampullary neoplasms. , 2021, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].
[19] C. V. van Eijck,et al. Preoperative misdiagnosis of pancreatic and periampullary cancer in patients undergoing pancreatoduodenectomy: A multicentre retrospective cohort study. , 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[20] N. Kumari,et al. Identification of PI3K-AKT signaling as the dominant altered pathway in intestinal type ampullary cancers through whole-exome sequencing , 2021, Journal of pathology and translational medicine.
[21] C. Dejong,et al. A population-based study on incidence, treatment, and survival in ampullary cancer in the Netherlands. , 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[22] A. Ejaz,et al. Neoadjuvant therapy versus surgery first for ampullary carcinoma: A propensity score‐matched analysis of the NCDB , 2021, Journal of surgical oncology.
[23] C. Strassburg,et al. Improving quality of life in pancreatic cancer patients following high-intensity focused ultrasound (HIFU) in two European centers , 2021, European Radiology.
[24] Namita S. Gandhi,et al. Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial. , 2021, JAMA oncology.
[25] Rong Liu,et al. Comment On "500 Minimally Invasive Robotic Pancreatoduodenectomies: One Decade of Optimizing Performance". , 2020, Annals of surgery.
[26] N. Kumari,et al. Prevalence and spectrum of pathogenic germline variants in intestinal and pancreatobiliary type of ampullary cancer. , 2020, Pathology, research and practice.
[27] R. Greil,et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. , 2020, The Lancet. Oncology.
[28] G. Williams,et al. The Clinical Benefit of Adjuvant Therapy in Long-Term Survival of Early-Stage Ampullary Carcinoma: A Single Institutional Experience , 2020, Journal of clinical medicine research.
[29] R. Gray,et al. Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Yanming Zhou,et al. Prognostic factors and benefits of adjuvant therapy for ampullary cancer following pancreatoduodenectomy: A systematic review and meta-analysis. , 2020, Asian journal of surgery.
[31] G. Fontanini,et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. , 2020, The Lancet. Oncology.
[32] M. Katz,et al. Management of ampullary adenomas in familial adenomatous polyposis syndrome: 16 years of experience from a tertiary cancer center. , 2020, Gastrointestinal endoscopy.
[33] A. Chen,et al. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] J. Weitz,et al. Adjuvant therapy is associated with improved overall survival in patients with pancreatobiliary or mixed subtype ampullary cancer after pancreatoduodenectomy - A multicenter cohort study. , 2020, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].
[35] Lianchun Xiao,et al. Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers , 2020, World journal of gastrointestinal oncology.
[36] L. Diaz,et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] A. Drilon,et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. , 2019, The Lancet. Oncology.
[38] S. Detlefsen,et al. Mutational profiling and immunohistochemical analysis of a surgical series of ampullary carcinomas , 2019, Journal of Clinical Pathology.
[39] Jae Hoon Lee,et al. Laparoscopic pancreaticoduodenectomy for periampullary tumors: lessons learned from 500 consecutive patients in a single center , 2019, Surgical Endoscopy.
[40] D. Adler,et al. Demographics, tumor characteristics, treatment, and clinical outcomes of patients with ampullary cancer: a Surveillance, Epidemiology, and End Results (SEER) cohort study. , 2019, Minerva gastroenterologica e dietologica.
[41] D. Morton,et al. FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer. , 2019, Journal of Clinical Oncology.
[42] S. Kumer,et al. Clinical Outcome of Ampullary Carcinoma: Single Cancer Center Experience , 2019, Journal of oncology.
[43] Jin‐Young Jang,et al. Recurrence patterns after pancreaticoduodenectomy for ampullary cancer , 2019, Journal of hepato-biliary-pancreatic sciences.
[44] B. Taylor,et al. Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes , 2019, Cancer.
[45] P. Rabinovitch,et al. Diagnosis, risk stratification, and management of ampullary dysplasia by DNA flow cytometric analysis of paraffin-embedded tissue , 2019, Modern Pathology.
[46] J. Raftery,et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. , 2019, The Lancet. Oncology.
[47] A. Barkun,et al. Endoscopic Resection of Ampullary Tumours: Long-term Outcomes and Adverse Events , 2019, Journal of the Canadian Association of Gastroenterology.
[48] Thierry Lecomte,et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer , 2018, The New England journal of medicine.
[49] A. El Nakeeb,et al. Predictors of long-term survival after pancreaticoduodenectomy for peri-ampullary adenocarcinoma: A retrospective study of 5-year survivors. , 2018, Hepatobiliary & pancreatic diseases international : HBPD INT.
[50] Sung-Sik Han,et al. Very early recurrence following pancreaticoduodenectomy in patients with ampullary cancer , 2019, Medicine.
[51] M. Bruno,et al. Endoscopic resection of advanced ampullary adenomas: a single-center 14-year retrospective cohort study , 2018, Surgical Endoscopy.
[52] J. Wan,et al. Ampullary adenocarcinoma: Defining predictors of survival and the impact of adjuvant therapy following surgical resection for stage I disease , 2018, Journal of Surgical Oncology.
[53] D. Nagorney,et al. Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience. , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[54] M. Choti,et al. Association of Adjuvant Therapy with Improved Survival in Ampullary Cancer: A National Cohort Study , 2018, Journal of Gastrointestinal Surgery.
[55] M. Choti,et al. Determining the Adequate Examined Lymph Node Count in Resected Ampullary Adenocarcinoma—A National Cohort Study , 2018, Journal of Gastrointestinal Surgery.
[56] S. Kamarajah. Adjuvant radiotherapy following pancreaticoduodenectomy for ampullary adenocarcinoma improves survival in node-positive patients: a propensity score analysis , 2018, Clinical and Translational Oncology.
[57] Funda Meric-Bernstam,et al. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.
[58] M. Sawyer,et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] R. Stupp,et al. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study , 2018, BMC Cancer.
[60] J. Hainsworth,et al. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] P. Senthilnathan,et al. Randomized clinical trial of laparoscopic versus open pancreatoduodenectomy for periampullary tumours , 2017, The British journal of surgery.
[62] M. Jung,et al. Therapeutic outcomes of endoscopic papillectomy for ampullary neoplasms: retrospective analysis of a multicenter study , 2017, BMC Gastroenterology.
[63] M. Choti,et al. Minimally Invasive Versus Open Pancreaticoduodenectomy: A Propensity-matched Study From a National Cohort of Patients , 2017, Annals of surgery.
[64] M. Büchler,et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial , 2017, The Lancet.
[65] D. Shibata,et al. Management and outcomes following pancreaticoduodenectomy for ampullary adenocarcinoma. , 2017, American journal of surgery.
[66] Jeffrey E. Lee,et al. Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater , 2017, Annals of Surgical Oncology.
[67] Z. Wang,et al. A pilot phase II study of neoadjuvant triplet chemotherapy regimen in patients with locally advanced resectable colon cancer , 2016, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.
[68] M. Reni,et al. Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer , 2016, British Journal of Cancer.
[69] S. Gill,et al. PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] A. Krasinskas,et al. Ampullary carcinoma is often of mixed or hybrid histologic type: an analysis of reproducibility and clinical relevance of classification as pancreatobiliary versus intestinal in 232 cases , 2016, Modern Pathology.
[71] H. Jang,et al. KRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review , 2016, Oncotarget.
[72] David Goldstein,et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. , 2016, JAMA.
[73] M. Kwon,et al. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value. , 2016, Human pathology.
[74] Jin‐Young Jang,et al. Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer , 2016, PloS one.
[75] Seung‐Mo Hong,et al. Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma , 2016, Modern Pathology.
[76] R. Higuchi,et al. Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma. , 2016, Cancer cell.
[77] Yan-Shen Shan,et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial , 2016, The Lancet.
[78] R. Gibbs,et al. Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. , 2016, Cell reports.
[79] R. Salem,et al. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer , 2016, British Journal of Cancer.
[80] W. Bernardo,et al. Endoscopic versus surgical treatment of ampullary adenomas: a systematic review and meta-analysis , 2016, Clinics.
[81] S. Kalloger,et al. Immunophenotyping of ampullary carcinomata allows for stratification of treatment specific subgroups , 2015, Journal of Clinical Pathology.
[82] G. Fontanini,et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. , 2015, The Lancet. Oncology.
[83] V. Heinemann,et al. Histomorphologic and molecular phenotypes predict gemcitabine response and overall survival in adenocarcinoma of the ampulla of Vater. , 2015, Surgery.
[84] Kyubo Kim,et al. Survival Benefit of Adjuvant Chemoradiotherapy in Patients With Ampulla of Vater Cancer: A Systematic Review and Meta-analysis. , 2015, Annals of surgery.
[85] A. Maitra,et al. Validation of histomolecular classification utilizing histological subtype, MUC1, and CDX2 for prognostication of resected ampullary adenocarcinoma , 2015, British Journal of Cancer.
[86] L. Borsu,et al. Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2) , 2015, Modern Pathology.
[87] C. Yang,et al. Long-term prognosis of surgical treatment for early ampullary cancers and implications for local ampullectomy , 2015, BMC Surgery.
[88] A. Krasinskas,et al. Substaging Nodal Status in Ampullary Carcinomas has Significant Prognostic Value: Proposed Revised Staging Based on an Analysis of 313 Well-Characterized Cases , 2015, Annals of Surgical Oncology.
[89] T. V. van Gulik,et al. Impact of lymph node ratio on survival in patients with pancreatic and periampullary cancer , 2015, The British journal of surgery.
[90] M. Al-Haddad,et al. Performance characteristics of EUS for locoregional evaluation of ampullary lesions. , 2015, Gastrointestinal endoscopy.
[91] K. Lillemoe,et al. Survival in ampullary cancer: potential role of different KRAS mutations. , 2015, Surgery.
[92] S. Fesik,et al. Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.
[93] Laura H. Tang,et al. The Utility of Immunohistochemistry in Subtyping Adenocarcinoma of the Ampulla of Vater , 2014, The American journal of surgical pathology.
[94] F. Que,et al. Adenomas of the Ampulla of Vater: A comparison of Outcomes of Operative and Endoscopic Resections , 2014, Journal of Gastrointestinal Surgery.
[95] M. Kornmann,et al. Survival and prognostic factors in pancreatic and ampullary cancer. , 2014, Anticancer research.
[96] G. Puhl,et al. Prognostic Factors for Long-Term Survival in Patients with Ampullary Carcinoma: The Results of a 15-Year Observation Period after Pancreaticoduodenectomy , 2014, HPB surgery : a world journal of hepatic, pancreatic and biliary surgery.
[97] Y. Igarashi,et al. Endosonographic Preoperative Evaluation for Tumors of the Ampulla of Vater Using Endoscopic Ultrasonography and Intraductal Ultrasonography , 2014, Clinical endoscopy.
[98] S. Sherman,et al. Endoscopic papillectomy: risk factors for incomplete resection and recurrence during long-term follow-up. , 2014, Gastrointestinal endoscopy.
[99] T. Ponchon,et al. Endoscopic papillectomy for early ampullary tumors: long-term results from a large multicenter prospective study , 2014, Endoscopy.
[100] Shin-E Wang,et al. Longterm survival after pancreaticoduodenectomy for periampullary adenocarcinomas. , 2013, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[101] S. Connor,et al. Review of the investigation and surgical management of resectable ampullary adenocarcinoma. , 2013, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[102] David Goldstein,et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.
[103] A. Hinke,et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. , 2013, JAMA.
[104] N. Kumari,et al. Intestinal and pancreatobiliary differentiation in periampullary carcinoma: the role of immunohistochemistry. , 2013, Human pathology.
[105] D. Shin,et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. , 2013, The Lancet. Oncology.
[106] A. Parikh,et al. Epidermal Growth Factor Receptor Signaling Pathway is Frequently Altered in Ampullary Carcinoma at Protein and Genetic Levels , 2013, Modern Pathology.
[107] C. Bassi,et al. Adequacy of Lymph Node Retrieval for Ampullary Cancer and Its Association with Improved Staging and Survival , 2013, World Journal of Surgery.
[108] J. K. Lee,et al. Prediction of Carcinoma After Resection in Subjects With Ampullary Adenomas on Endoscopic Biopsy , 2013, Journal of clinical gastroenterology.
[109] J. Kench,et al. Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[110] A. Azmy,et al. Oxaliplatin and Bolus-Modulated 5-Fluorouracil as a Second-Line Treatment for Advanced Pancreatic Cancer: Can Bolus Regimens Replace FOLFOX When Considered for Second Line? , 2013, ISRN oncology.
[111] Dawn M. Emick,et al. Endoscopic Versus Surgical Ampullectomy: An Algorithm to Treat Disease of the Ampulla of Vater , 2013, Annals of surgery.
[112] O. Clausen,et al. Reclassification of tumour origin in resected periampullary adenocarcinomas reveals underestimation of distal bile duct cancer. , 2012, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[113] E. Raymond,et al. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. , 2012, World journal of gastroenterology.
[114] M. Büchler,et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. , 2012, JAMA.
[115] S. Barni,et al. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study , 2012, Cancer Chemotherapy and Pharmacology.
[116] C. Willett,et al. Carcinoma of the Ampulla of Vater: Patterns of Failure Following Resection and Benefit of Chemoradiotherapy , 2012, Annals of Surgical Oncology.
[117] David Cella,et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[118] J. Cameron,et al. Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital - Mayo Clinic collaborative study , 2011, Radiation oncology.
[119] K. Almhanna,et al. Predictors of clinical outcomes of resected ampullary adenocarcinoma: a single-institution experience. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[120] T. Desser,et al. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. , 2011, International journal of radiation oncology, biology, physics.
[121] B. Dörken,et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. , 2011, European journal of cancer.
[122] K. Hatakeyama,et al. Assessment of the Nodal Status in Ampullary Carcinoma: The Number of Positive Lymph Nodes Versus the Lymph Node Ratio , 2011, World Journal of Surgery.
[123] Pierre Michel,et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.
[124] C. Yeo,et al. The Influence of Prognostic Factors and Adjuvant Chemoradiation on Survival After Pancreaticoduodenectomy for Ampullary Carcinoma , 2011, Journal of Gastrointestinal Surgery.
[125] F. D. De Braud,et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[126] Y. Kawabata,et al. Cytokeratin 20 (CK20) and apomucin 1 (MUC1) expression in ampullary carcinoma: Correlation with tumor progression and prognosis , 2010, Diagnostic pathology.
[127] D. Cunningham,et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. , 2010, The New England journal of medicine.
[128] M. Choti,et al. Clinicopathologic Analysis of Ampullary Neoplasms in 450 Patients: Implications for Surgical Strategy and Long-Term Prognosis , 2010, Journal of Gastrointestinal Surgery.
[129] M. Bloomston,et al. Predictors of Survival in Periampullary Cancers Following Pancreaticoduodenectomy , 2010, Annals of Surgical Oncology.
[130] T. Gauler,et al. Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ , 2010, Anti-cancer drugs.
[131] G. Stamp,et al. Survival analysis after pancreatic resection for ampullary and pancreatic head carcinoma: An analysis of clinicopathological factors , 2009, Journal of surgical oncology.
[132] W. Scheithauer,et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[133] L. Traverso,et al. Papillectomy for ampullary neoplasm: results of a single referral center over a 10-year period. , 2009, Gastrointestinal endoscopy.
[134] D. Park,et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer , 2009, British Journal of Cancer.
[135] A. Bellizzi,et al. The assessment of specimens procured by endoscopic ampullectomy. , 2009, American journal of clinical pathology.
[136] P. Sakai,et al. Prospective evaluation of EUS versus CT scan for staging of ampullary cancer. , 2009, Gastrointestinal endoscopy.
[137] J. Cameron,et al. Adjuvant chemoradiation versus surgery alone for adenocarcinoma of the ampulla of Vater. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[138] Po-Huang Lee,et al. Is Blind Pancreaticoduodenectomy Justified for Patients with Ampullary Neoplasms? , 2009, Journal of Gastrointestinal Surgery.
[139] Jeffrey S. Morris,et al. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[140] A. Novarino,et al. Oxaliplatin, 5-Fluorouracil, and Leucovorin as Second-Line Treatment for Advanced Pancreatic Cancer , 2009, American journal of clinical oncology.
[141] Chien-Hua Chen,et al. Reappraisal of endosonography of ampullary tumors: Correlation with transabdominal sonography, CT, and MRI , 2009, Journal of clinical ultrasound : JCU.
[142] Wei-xing Chen,et al. Multiple imaging techniques in the diagnosis of ampullary carcinoma. , 2008, Hepatobiliary & pancreatic diseases international : HBPD INT.
[143] K. Hess,et al. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second‐line therapy for patients with advanced pancreatic cancer , 2008, Cancer.
[144] Jeffrey E. Lee,et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[145] Jeffrey E. Lee,et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[146] O. Clausen,et al. Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma , 2008, BMC Cancer.
[147] W. Scheithauer,et al. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[148] C. Ko,et al. Survival After Resection of Ampullary Carcinoma: A National Population-Based Study , 2008, Annals of Surgical Oncology.
[149] S. Hochwald,et al. Contemporary results with ampullectomy for 29 "benign" neoplasms of the ampulla. , 2008, Journal of the American College of Surgeons.
[150] Douglas B. Evans,et al. Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater. , 2008, International journal of radiation oncology, biology, physics.
[151] C. Fuchs,et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[152] N. Fujita,et al. Preoperative evaluation of ampullary neoplasm with EUS and transpapillary intraductal US: a prospective and histopathologically controlled study. , 2007, Gastrointestinal endoscopy.
[153] Jin‐Young Jang,et al. Recurrence and Prognostic Factors of Ampullary Carcinoma after Radical Resection: Comparison with Distal Extrahepatic Cholangiocarcinoma , 2007, Annals of Surgical Oncology.
[154] L. Crinò,et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[155] D. Stocken,et al. A Randomized Phase 2 Trial of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer: Gemcitabine Alone Versus Gemcitabine Combined with Cisplatin , 2007, Annals of Surgical Oncology.
[156] D. Yoon,et al. Factors influencing recurrence after curative resection for ampulla of vater carcinoma , 2007, Journal of surgical oncology.
[157] Y. Shan,et al. Predictors for Patterns of Failure after Pancreaticoduodenectomy in Ampullary Cancer , 2006, Annals of Surgical Oncology.
[158] J. Donohue,et al. Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience. , 2006, International journal of radiation oncology, biology, physics.
[159] V. Kapoor,et al. Long-term Survival and Recurrence Patterns in Ampullary Cancer , 2006, Pancreas.
[160] S. Choi,et al. Can endoscopic resection be applied for early stage ampulla of Vater cancer? , 2006, Gastrointestinal Endoscopy.
[161] J. Yeh,et al. Limitations of Ampullectomy in the Treatment of Nonfamilial Ampullary Neoplasms , 2005, Annals of Surgical Oncology.
[162] N. Soehendra,et al. Endoscopic resection of benign tumors of the duodenal papilla without and with intraductal growth. , 2005, Gastrointestinal endoscopy.
[163] E. Felekouras,et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study , 2005, Investigational New Drugs.
[164] Markus Abt,et al. Capecitabine as adjuvant treatment for stage III colon cancer. , 2005, The New England journal of medicine.
[165] M. Shoup,et al. Pancreaticoduodenectomy is curative in the majority of patients with node-negative ampullary cancer. , 2005, Archives of surgery.
[166] F. Rotondi,et al. Pancreatoduodenectomy for Tumors of Vater’s Ampulla: Report on 94 Consecutive Patients , 2005, World Journal of Surgery.
[167] Abnish Kumar,et al. Adjuvant chemo-radiotherapy in ampullary cancers. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[168] R. Parks,et al. Presentation, treatment and outcome in patients with ampullary tumours , 2004, The British journal of surgery.
[169] S. Sherman,et al. Endoscopic snare papillectomy for tumors of the duodenal papillae. , 2004, Gastrointestinal endoscopy.
[170] J. Buckels,et al. Favourable Prognostic Factors in a Large UK Experience of Adenocarcinoma of the Head of the Pancreas and Periampullary Region , 2004, Digestive Surgery.
[171] T. Hickish,et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.
[172] Helen Hickey,et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. , 2004, The New England journal of medicine.
[173] M. Catalano,et al. Endoscopic management of adenoma of the major duodenal papilla. , 2004, Gastrointestinal endoscopy.
[174] C. Ko,et al. Improved survival for adenocarcinoma of the ampulla of Vater: fifty-five consecutive resections. , 2003, Archives of surgery.
[175] J. Berlin,et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[176] F. Borda,et al. How accurate is preoperative diagnosis by endoscopic biopsies in ampullary tumours? , 2002, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.
[177] G. Alexandrakis,et al. Is endosonography an effective method for detection and local staging of the ampullary carcinoma? A prospective study , 2002, BMC surgery.
[178] E. Van Cutsem,et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[179] L. Mo,et al. The accuracy of endoscopic ultrasound, endoscopic retrograde cholangiopancreatography, computed tomography, and transabdominal ultrasound in the detection and staging of primary ampullary tumors. , 2001, Hepato-gastroenterology.
[180] A. Scarpa,et al. Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis , 2001, British Journal of Cancer.
[181] C. Wilson,et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[182] D. Tyler,et al. Local ampullary resection with careful intraoperative frozen section evaluation for presumed benign ampullary neoplasms. , 2000, Surgery.
[183] J. Jeekel,et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. , 1999, Annals of surgery.
[184] C. Poremba,et al. Tumors of the papilla of Vater--inadequate diagnostic impact of endoscopic forceps biopsies taken prior to and following sphincterotomy. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[185] J. Lotz,et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. , 1999, European journal of cancer.
[186] E. Rosato,et al. EUS compared with CT, magnetic resonance imaging, and angiography and the influence of biliary stenting on staging accuracy of ampullary neoplasms. , 1999, Gastrointestinal endoscopy.
[187] T. Mattfeldt,et al. Tumor of the ampulla of Vater: experience with local or radical resection in 171 consecutively treated patients. , 1999, Archives of surgery.
[188] G. Beck,et al. The natural history of untreated duodenal and ampullary adenomas in patients with familial adenomatous polyposis followed in an endoscopic surveillance program. , 1999, Gastrointestinal endoscopy.
[189] R. Labianca,et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.
[190] G. Capellá,et al. Cancers of the papilla of vater: mutator phenotype is associated with good prognosis. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[191] A. Scarpa,et al. APC gene mutations and allelic losses in sporadic ampullary tumours: Evidence of genetic difference from tumours associated with familial adenomatous polyposis , 1996, International journal of cancer.
[192] D. Rattner,et al. Defining the criteria for local resection of ampullary neoplasms. , 1996, Archives of surgery.
[193] T. V. van Gulik,et al. Results of pancreaticoduodenectomy for ampullary carcinoma and analysis of prognostic factors for survival. , 1995, Surgery.
[194] T. Muto,et al. Different Clinicopathologic Findings in Two Histologic Types of Carcinoma of Papilla of Vater , 1994, Japanese journal of cancer research : Gann.
[195] Eric A. Swanson,et al. Association of Histopathologic Phenotype of Periampullary Adenocarcinomas With Survival , 2017, JAMA surgery.
[196] P. Senthilnathan,et al. Long-term results of laparoscopic pancreaticoduodenectomy for pancreatic and periampullary cancer-experience of 130 cases from a tertiary-care center in South India. , 2015, Journal of laparoendoscopic & advanced surgical techniques. Part A.
[197] M. Makary,et al. 2564 resected periampullary adenocarcinomas at a single institution: trends over three decades. , 2014, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[198] T. Bekaii-Saab,et al. Ampullary cancer: an overview. , 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[199] W. Regine,et al. Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers. , 2011, International journal of radiation oncology, biology, physics.
[200] G. Elek,et al. Histological evaluation of preoperative biopsies from ampulla Vateri , 2009, Pathology Oncology Research.
[201] Yinmo Yang,et al. Carcinoma of the Ampulla of Vater: Factors Influencing Long-term Survival of 127 Patients with Resection , 2006, World Journal of Surgery.
[202] N. Ohkohchi,et al. Patterns and Predictors of Failure after Curative Resections of Carcinoma of the Ampulla of Vater , 2003, Annals of Surgical Oncology.
[203] M. Stolte,et al. Adenoma-carcinoma sequence in the papilla of Vater. , 1996, Scandinavian journal of gastroenterology.